A non-trivial fraction of people cannot afford to buy pharmaceutical products at unregulated market prices. This paper analyses the public insurance of a patent-protected pharmaceutical product in terms of price controls and socially optimal third-degree price discrimination. First, the paper...

Background Within Finland's breast cancer screening program, all women aged 50-69 are invited to biennial screening. Current European guidelines recommend screening in ages 45-49 and 70-74 conditional upon, inter alia, demonstrated context-specific cost-effectiveness. This study aims to...